Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT Crossover design	29 people with chronic pancreatitis, 27 (93%) alcohol-induced, 28 men, mean age 53 years, with faecal fat >10 g/day In review	Blood glucose control 4 weeks with pancreatin (4 capsules at meal times and 2 with snack) with placebo	Significance not assessed
RCT	27 people with chronic pancreatitis, 9 men, mean age 51 years, faecal fat values greater than or equal to 10 g/day and/or a fat absorption <80% In review	Non-serious adverse effects (include nausea, mild tremor, mild weakness, and abdominal pain) 2 weeks 6/13 (46%) with pancreatin (4 capsules at meal times and 2 with snacks) 11/14 (79%) with placebo	P = 0.5		Not significant
RCT	27 people with chronic pancreatitis, 9 men, mean age 51 years, faecal fat values greater than or equal to 10 g/day and/or a fat absorption <80% In review	Serious adverse effects 2 weeks 0/13 (0%) with pancreatin (4 capsules at meal times and 2 with snacks) 0/14 (0%) with placebo	Significance not assessed